FTRE Stock Analysis: Buy, Sell, or Hold?

FTRE - Fortrea Holdings Inc. Common Stock

SERVICES-MEDICAL LABORATORIES
$19.31
0.14 (0.73%) ▲
5d: +0.57%
30d: +11.75%
90d: +58.54%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026 0d

Get Alerted When FTRE Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: FTRE shows positive signals but monitor for confirmation. Market pricing in 3.9% growth. Moderate conviction.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$33.33
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$20.70
6.7% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: FTRE is currently trading at $19.31, which is considered slightly high relative to its 30-day fair value range of $17.32 to $19.20. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.1) compared to its historical average (15.3). At these levels, the market is pricing in 3.9% annual earnings growth.

Technical Outlook: Technically, FTRE is in a strong uptrend. Immediate support is located at $17.37, while resistance sits at $21.39.

Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $17.32 - $19.20
Company Quality Score 56/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 63.8%

All Signals

  • NEUTRAL: Mixed technical signals (55/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($19.94)
  • BULLISH: Expecting earnings turnaround to 3.9% growth with -4.5% revenue growth

Trading Range Analysis

30-Day Trading Range $17.32 - $19.20
Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $17.37
Resistance Level $21.39
Current Trend Strong Uptrend
Technical data as of Aug 3, 2026

Fundamental Context

Forward P/E (Next Year Est.) 17.14
Wall Street Target $19.94 (+4.0%)
Revenue Growth (YoY) -4.5%
Earnings Growth (YoY) -57.4%
Profit Margin -3.2%
Valuation Premium vs History +3.9% premium
PE vs Historical 17.1 vs 15.3 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +3.9% (market-implied from PE analysis)
1-Year Target $19.92 (+4%)
2-Year Target $20.69 (+8%)
3-Year Target $21.50 (+12%)
3-Yr Target (if PE normalizes) (PE: 17→15) PE COMPRESSION $19.20 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.7, Growth: 34.9%) $56.93 (+197%)
Base: (SPY PE: 17.1, Growth: 34.9%) $47.06 (+146%)
Bear: (PE: 14.6, Growth: 34.9%) $40.00 (+109%)
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 03, 2026 3:41 PM ET
Data refreshes hourly during market hours. Next update: 4:41 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Jill G Mcconnell SELL 1804 shares 2026-03-16
Jill G Mcconnell SELL 5061 shares 2026-03-10
Robert Parks SELL 1927 shares 2026-03-10

Unlock Insider Activity

See real-time buying/selling by company executives for FTRE.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NTLA
Intellia Therapeutics Inc
STRONG BUY
29 analysts
$26 50 HOLD
SRPT
Sarepta Therapeutics Inc
STRONG BUY
26 analysts
$22 49 HOLD
ARGX
argenx NV ADR
STRONG BUY
22 analysts
$1080 57 HOLD
LEGN
Legend Biotech Corp
STRONG BUY
22 analysts
$52 54 HOLD
KYMR
Kymera Therapeutics Inc
STRONG BUY
20 analysts
$127 59 HOLD

More Analysis for FTRE

FTRE Technical Chart FTRE Price Prediction FTRE Earnings Date FTRE Investment Advisor FTRE Fair Price Analyzer FTRE Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals